Study Identifies microRNA Driving Triple-Negative Breast Cancer

Researchers found miR-1290 from tumor-surrounding fibroblasts promotes cancer cell growth, and the approved drug everolimus suppressed it in experiments.

Updated on Nov. 12, 2026 in Cancer

Bold flat-color editorial illustration of two clusters of translucent teal spheres with one small orange sphere passing between them, evoking a molecular transfer tied to breast cancer cell growth.
Researchers found that the microRNA miR-1290, carried from tumor-surrounding fibroblasts, promotes growth of triple-negative breast cancer cells, and the approved drug everolimus suppressed it in experiments. AI Illustration. Upload story photo >

Researchers identified how miR-1290, a microRNA transferred from fibroblasts surrounding tumors, promotes growth of triple-negative breast cancer cells, according to a study published online on September 20 in Signal Transduction and Targeted Therapy. Experiments showed the approved drug everolimus suppressed miR-1290-induced cancer cell proliferation.

Why it matters

Triple-negative breast cancer accounts for approximately 10-15% of all breast cancer cases, and treatment has relied largely on chemotherapy because targeted therapies used for other breast cancer types have limited applicability. The findings may help guide new targeted therapies and more precise diagnostic criteria for these patients.

The study is a laboratory and exosome-analysis investigation rather than a clinical trial, with miR-1290 linked to reduced TBC1D4 levels and associated with poorer outcomes in patient blood samples. Whether everolimus would benefit patients with this mechanism remains untested in human treatment studies.

The players

Korea Research Institute of Bioscience and Biotechnology (KRIBB)

KRIBB is a South Korean government-funded research institute focused on biotechnology and life sciences research.

Kyungpook National University

Kyungpook National University is a public research university in Daegu, South Korea, that collaborated on the study.

The details

miR-1290 entered triple-negative breast cancer cells and reduced levels of TBC1D4, a protein that helps suppress tumor growth. The researchers identified the microRNA by analyzing the contents of exosomes released by cancer-associated fibroblasts and breast cancer cells, and the study was led by researchers at the Korea Research Institute of Bioscience and Biotechnology with Kyungpook National University.

Timeline

  1. September 20: Study published online in Signal Transduction and Targeted Therapy.

Health Landscape

Triple-negative breast cancer has lacked targeted therapies comparable to those used for other breast cancer subtypes, which is why chemotherapy has remained central. This research points toward repurposing approved growth-inhibiting drugs such as everolimus as a possible route to treatments with a molecular rationale.

For patients with triple-negative breast cancer, this research does not yet change available treatment, which still relies largely on chemotherapy. Any future use of everolimus or microRNA-based diagnostics would require clinical testing before it reaches patients.

The takeaway

Blood levels and tumor-environment signals like miR-1290 may someday help identify which triple-negative breast cancer patients need different treatment. Such approaches remain experimental and will require clinical validation before they influence care.

Further reading

Explore more on Cancer research and treatment developments.

More information

Read the full published study in Signal Transduction and Targeted Therapy.

Source note: This article includes information reported by News-Medical.